PDCD1 and cancer: We analyzed SCFAs levels in anti-PD-1-treated cancer patients and observed that the serum from patients who responded (complete response + partial response + stable disease) to anti-PD-1 therapy showed higher acetic acid, propionic acid, and butyric acid abundance than that of non-responding patients (Figure 1e–g).